Serum total sialic acid and Hanganutziu-Deicher antibody in normals and in cancer patients

East African Medical Journal

Volumn 84, Issue 5, 2007, Pages 207-214

  Kanduma, E G ^a   Mukuria, J C ^a   Mwanda, O W ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROPHILE ANTIBODY; N ACETYLNEURAMINIC ACID; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CARCINOMA; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KENYA; LYMPHOMA; MALE; MIDDLE AGED; SARCOMA; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, HETEROPHILE; CARCINOMA; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; KENYA; LYMPHOMA; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 34547438902     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Painbeni T., Gamelin E., Cailleux A., et al. Plasma total sialic acids as marker of the effect of the treatment on metastatic colorectal cancer. Eur. J. Cancer. 1997; 33: 2216-2220.
2. Tuppy H. and Gottschalk A. Glycoproteins, their composition, structure and function. Gottschalk, A., ed. B. B.A Library, Elsevier Publishing Co., Amsterdam, London, New York. 1972; 5: 403-449.
3. Ng S.S. and Dain J.A. Biological roles of sialic acid. Rosenberg, A. and Schengrund, C.L., eds. Plenum Press, New York, London. 1976; 59-102.
4. Corfield A.P. and Schauer R. Cell Biol. Monogr. 1982; 10: 5-55.
5. Kozutsumi Y., Kawano T., Kawasaki H., et al. Reconstitution of CMP-N-acetylneuraminic acid hydroxylation activity using a mouse liver cytosol fraction and soluble cytochrome b5 purified from horse erythrocytes. J. Biochem. 1991; 110: 429-435.
6. Shaw, L., Schneckenburger P., Schlenzka W., et al. CMP-N-acetylneuraminic acid hydroxylase from mouse liver and pig submandibular glands. Interaction with membrane-bound and soluble cytochrome b5-dependent electron transport chains. Eur. J. Biochem. 1994; 219: 1001-1011.
7. Mukuria J.C., Mwangi D.W., Noguchi A., et al. Evidence of a free N-acetylneuraminic acid hydroxylating enzyme in pig mandibular soluble fraction. Biochem. J. 1995; 305: 459464.
8. Mukuria J.C., Naiki M., Hashimoto M. and Kato S. A specific enzyme-linked immunosorbent assay (ELISA) procedure for detection of heterophile Hanganutziu and Deicher (HD) antibodies. J. Immunol. Methods. 1986; 86: 179-185.
9. Higashigara T., Takeshima T., Anzai M., et al. Survey of Hanganutziu and Deicher antibodies in operated patients. Int. Arch. Allergy Appl. Immunol. 1991; 95: 231-235.
10. Ikuta K., Kitamoto N., Shoji H., et al. Hanganutziu and Deicher type heterophile antigen expressed on the cell surface of Marek's disease lymphoma-derived cell lines. Biken J. 1981; 24: 23-27.
11. Fujii Y., Higashi H., Jkuta K., et al. Specificities of human heterophilic Hanganutziu and Deicher (HD) antibodies and avian antisera against HD antigen-active glycosphingolipids. Mol. Immunol. 1982; 19: 87-94.
12. Katopodis N., Hirshaut Y., Geller N.L. and Stock CC Lipid associated sialic test for the detection of human cancer. Cancer Res. 1982; 42: 5270-5275.
13. Raval G.N., Patel D.D., Parekh L.J., et al. Evaluation of serum total sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. Oral Dis. 2003; 9: 119-128.
14. Basoglu M., Yildirgan M.I., Taysi S., et al. Levels of soluble intercellular adhesion molecule-1 and total sialic acid in serum of patients with colorectal cancer. J. Surg. Oncol. 2003; 83: 180-184.
15. Shamberger R.J. Serum total sialic acid in normals and cancer patients. J. Clin. Chem. Clin. Biochem. 1984; 22: 647-651.
16. Shashikanfh M.C and Rae B.B. Study of serum fucose and serum total sialic acid levels in oral squamous cell carcinoma. Indian J. Dent. Res. 1994; 5: 119-124.
17. Feijoo-Carnero C., Rodriguez-Berrocal F.J., Paez de la Cadena M., et al. Clinical significance of preoperative serum total sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumour recurrence. Int. J. Biol. Markers. 2004; 19: 38-45.